Stocks · Health care · Pharmaceutical Preparations

Dianthus Therapeutics, Inc.

DNTH Clue Score33
United States Fiscal year ends December CIK 0001690585 Results filed 4 Nov 2026

What the insiders did Scheduled selling only

By person

8 insiders · 69 transactions
10.8×

Marino Garcia holds 10.8 times base salary in stock. $6.82M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $104.39, the price Common Stock was last bought or sold at on the open market here, on 17 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Marino Garcia
CEO and President
—
$27.96M (12) scheduled
−$27.96M
65,292
0.1167%
$6.82M
—
Simrat Randhawa
EVP, Head of R&D
—
$15.00M (11) scheduled
−$15.00M
4,000
0.0072%
$417.56K
0.0%
Ryan Savitz
EVP, CFO & Cbo
—
$14.29M (13) scheduled
−$14.29M
0
0.0000%
$0.00
—
Edward Carr
Chief Accounting Officer
—
$5.59M (10) scheduled
−$5.59M
0
0.0000%
$0.00
—
Adam M Veness
SVP, General Counsel and Sec.
—
$4.63M (5) scheduled
−$4.63M
15,000
0.0268%
$1.57M
—
Paula Soteropoulos
Director
—
$2.25M (3) scheduled
−$2.25M
0
0.0000%
$0.00
—
Anne McGeorge
Director
—
$844.82K (5) scheduled
−$844.82K
0
0.0000%
$0.00
—
Simon Read
Director
—
$630.79K (7) scheduled
−$630.79K
0
0.0000%
$0.00
—